Twist Bioscience Corp Stock Research

Market Summary

USD16.18+0.20

Market Closed

1.25%

TWST Alerts

Big jump in Revenue (Y/Y)
Losses in recent quarter

TWST Stock Price

TWST RSI Chart

TWST Valuation

Market Cap

916.5M

Price/Earnings (Trailing)

-4.28

Price/Sales (Trailing)

4.25

EV/EBITDA

-3.07

Price/Free Cashflow

-3.94

TWST Price/Sales (Trailing)

TWST Profitability

Operating Margin

43.59%

EBT Margin

-99.20%

Return on Equity

-28.69%

Return on Assets

-23.53%

Free Cashflow Yield

-25.39%

TWST Fundamentals

TWST Revenue

Revenue (TTM)

215.8M

Revenue Y/Y

29.09%

Revenue Q/Q

-5.34%

TWST Earnings

Earnings (TTM)

-214.1M

Earnings Y/Y

8.21%

Earnings Q/Q

18.18%

Price Action

52 Week Range

14.9858.76

(Low)(High)

Last 7 days

-3.6%

Last 30 days

-22.3%

Last 90 days

-30.2%

Trailing 12 Months

-65.9%

TWST Financial Health

Current Ratio

6.46

TWST Investor Care

Shares Dilution (1Y)

13.49%

Diluted EPS (TTM)

-3.84

Peers (Alternatives to Twist Bioscience)

View All Peers In Detail

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
AMGN	127.1B	26.3B	0.79%	2.78%	19.4	4.83	1.32%	11.18%
GILD	99.8B	27.3B	-4.19%	39.66%	21.72	3.66	-0.09%	-26.23%
MRNA	58.1B	19.3B	-4.61%	-16.03%	6.95	3.02	4.29%	-31.47%
BIIB	39.0B	10.2B	-0.92%	26.77%	12.8	3.83	-7.36%	95.80%
MID-CAP
NBIX	9.4B	1.5B	-5.59%	3.19%	60.62	6.29	31.34%	72.43%
DNLI	3.1B	108.5M	-21.66%	-32.82%	-9.55	28.71	122.90%	-12.19%
BBIO	2.2B	107.9M	21.83%	38.60%	-4.63	20.79	54.84%	17.36%
BEAM	2.2B	60.9M	-25.55%	-48.21%	-7.49	35.56	17.51%	22.00%
SMALL-CAP
RCUS	1.3B	112.0M	-7.70%	-49.25%	-4.81	11.47	-70.76%	-603.77%
REPL	1.1B	7.0M	-17.00%	22.02%	-7.14	159.78	131.81%	-45.39%
FATE	524.4M	96.3M	-14.58%	-86.07%	-1.86	5.45	72.44%	-32.79%
NVAX	519.7M	2.0B	-33.63%	-92.58%	-0.79	0.26	72.89%	62.27%
SGMO	276.9M	111.3M	-42.96%	-71.96%	-1.44	2.49	0.54%	-7.86%
VXRT	101.6M	107.0K	-17.23%	-85.52%	-0.94	949.93	-88.00%	-52.91%
IBIO	26.0M	-	40.00%	-84.44%	-0.32	3.21	0.51%	-185.61%

Financials for Twist Bioscience

Income Statement (Last 12 Months)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Revenue	6.0%	215,789,000	203,565,000	184,209,000	163,114,000	146,191,000
S&GA Expenses	-4.1%	204,174,000	212,949,000	197,032,000	177,817,000	158,208,000
R&D Expenses	7.2%	128,919,000	120,307,000	110,144,000	93,142,000	77,702,000
EBITDA	7.7%	-195,356,000	-211,694,000	-204,221,000	-187,549,000	-
EBITDA Margin	12.9%	-0.91	-1.04	-1.11	-1.15	-
Earnings Before Taxes	6.2%	-214,054,000	-228,274,000	-218,352,000	-200,100,000	-177,141,000
EBT Margin	11.5%	-0.99	-1.12	-1.19	-1.23	-
Interest Expenses	-30.0%	56,000	80,000	138,000	208,000	274,000
Net Income	1.7%	-214,124,000	-217,863,000	-207,990,000	-187,510,000	-164,761,000
Net Income Margin	7.3%	-0.99	-1.07	-1.13	-1.15	-
Free Cahsflow	-2.9%	-232,700,000	-226,242,000	-251,405,000	-211,540,000	-

* denotes actual numbers (not divided by Millions)
Balance Sheet					(In Millions)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Assets	-5.3%	910	961	980	1,022	786
Current Assets	-9.2%	542	596	624	664	385
Cash Equivalents	-16.4%	317	379	376	408	193
Inventory	13.5%	45.00	39.00	43.00	45.00	40.00
Net PPE	3.9%	145	139	127	92.00	65.00
Goodwill	0%	86.00	86.00	86.00	86.00	84.00
Liabilities	-4.9%	164	172	159	158	160
Current Liabilities	-7.5%	84.00	91.00	93.00	85.00	80.00
LT Debt, Current	NaN%	-	-	-	-	-
Shareholder's Equity	-5.5%	746	789	821	863	626
Retained Earnings	-5.0%	-870	-828	-777	-716	-656
Additional Paid-In Capital	-0.2%	1,617	1,620	1,599	1,581	1,282
Shares Outstanding	0.2%	57.00	57.00	56.00	56.00	50.00

Cashflow (Last 12 Months)					(In Millions)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Cashflow From Operations	-6.0%	-131	-124	-157	-151	-133
Share Based Compensation	-25.6%	59.00	80.00	70.00	59.00	48.00
Cashflow From Investing	94.3%	-13.32	-232	-211	-111	-24.51
Cashflow From Financing	0.2%	271	271	271	271	1.00

Risks for TWST

What is the probability of a big loss on TWST?

97.4%

Probability that Twist Bioscience stock will be more than 20% underwater in next one year

97.0%

Probability that Twist Bioscience stock will be more than 30% underwater in next one year.

63.8%

Probability that Twist Bioscience stock will be more than 40% underwater in next one year.

*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does TWST drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Twist Bioscience was unfortunately bought at previous high price.

Drawdowns

Returns for TWST

Cumulative Returns on TWST

-15.4%

3-Year Cumulative Returns

Which funds bought or sold TWST recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
2023-03-15	B. Riley Wealth Advisors, Inc.	sold off	-100	-250,000	-	-%
2023-03-10	BAILLIE GIFFORD & CO	added	21.84	-5,550,360	25,847,600	0.03%
2023-03-10	VICTORY CAPITAL MANAGEMENT INC	sold off	-100	-10,620,000	-	-%
2023-03-06	Rockefeller Capital Management L.P.	reduced	-81.99	-840,000	116,000	-%
2023-02-28	Voya Investment Management LLC	added	0.71	-17,552,400	37,376,600	0.05%
2023-02-24	NATIXIS	sold off	-100	-2,892,000	-	-%
2023-02-21	MACQUARIE GROUP LTD	reduced	-43.51	-379,000	220,000	-%
2023-02-16	HARBOUR INVESTMENTS, INC.	new	-	500	500	-%
2023-02-15	Point72 Middle East FZE	new	-	15,929	15,929	-%
2023-02-15	Virtu Financial LLC	added	142	151,000	388,000	0.05%

Latest Funds Activity

Are funds buying TWST calls or puts?

Calls

Puts

Are funds bullish or bearish(Calls - Puts)?

Net Call Options

No. of funds that own TWST

No. of Funds

Twist Bioscience News

Schedule 13G FIlings of Twist Bioscience

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2023	capital world investors	1.2%	704,000	SC 13G/A
Feb 09, 2023	fmr llc	-	0	SC 13G/A
Feb 09, 2023	vanguard group inc	9.24%	5,229,345	SC 13G/A
Feb 03, 2023	state street corp	7.82%	4,426,249	SC 13G
Feb 03, 2023	sumitomo mitsui trust holdings, inc.	5.18%	2,934,033	SC 13G
Jan 24, 2023	blackrock inc.	9.7%	5,487,180	SC 13G/A
Jan 13, 2023	jpmorgan chase & co	6.7%	3,829,962	SC 13G
Jun 09, 2022	ark investment management llc	11.14%	6,267,721	SC 13G/A
Mar 10, 2022	fmr llc	-	0	SC 13G
Feb 11, 2022	capital world investors	8.9%	4,522,700	SC 13G/A

TWST Fair Value

Twist Bioscience fair value in different scenarios

The table shows the Fair Value estimates for Twist Bioscience for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.

Fair Value	Very Pessimistic	Pessimistic	Base Case	Optimistic	Very Optimistic
Very Low Inflation	3.95 -75.59%	4.74 -70.70%	7.37 -54.45%	12.04 -25.59%	21.39 32.20%
Current Inflation	3.89 -75.96%	4.60 -71.57%	6.89 -57.42%	10.91 -32.57%	18.90 16.81%
Very High Inflation	3.82 -76.39%	4.43 -72.62%	6.33 -60.88%	9.58 -40.79%	16.01 -1.05%

Historical Twist Bioscience Fair Value Estimates

Very Pessimistic Case

Pessimistic Case

Fair Value

Optimistic Case

Very Optimistic Case

Closing Stock Price

Recent SEC filings of Twist Bioscience

View All Filings

Date Filed	Form Type	Document
Mar 21, 2023	4	Insider Trading
Mar 21, 2023	4	Insider Trading
Mar 21, 2023	4	Insider Trading
Mar 21, 2023	4	Insider Trading
Mar 21, 2023	4	Insider Trading
Mar 15, 2023	4	Insider Trading
Mar 15, 2023	4	Insider Trading
Feb 22, 2023	4	Insider Trading
Feb 22, 2023	4	Insider Trading
Feb 22, 2023	4	Insider Trading

Latest Insider Trading transactions for TWST

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
2023-03-17	Cho Dennis	sold (taxes)	-4,210	16.51	-255	see remarks
2023-03-17	Leproust Emily M.	sold (taxes)	-28,859	16.51	-1,748	chief executive officer
2023-03-17	Banyai William	sold (taxes)	-6,901	16.51	-418	see remarks
2023-03-17	Green Paula	sold (taxes)	-3,962	16.51	-240	svp of human resources
2023-03-17	THORBURN JAMES M	sold (taxes)	-8,981	16.51	-544	chief financial officer
2023-03-13	Cho Dennis	sold (taxes)	-1,733	16.83	-103	see remarks
2023-02-17	Yankton Kevin Bruce	sold (taxes)	-1,351	22.52	-60.00	chief accounting officer
2023-02-17	Finn Patrick John	sold (taxes)	-23,128	22.52	-1,027	president and coo
2023-02-17	Leproust Emily M.	sold (taxes)	-61,727	22.52	-2,741	chief executive officer
2023-02-17	THORBURN JAMES M	sold (taxes)	-23,128	22.52	-1,027	chief financial officer

About Twist Bioscience

Emily M. Leproust

N/A

650

Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has collaboration agreements with Victorian Clinical Genetic Services; Vivlion GmbH.; Kyowa Kirin Pharmaceutical Research, Inc.; deepCDR Biologics AG; and Centogene N.V to develop advanced sequencing tools. It also has a research collaboration with Boehringer Ingelheim International GmbH to use proprietary antibody libraries to discover therapeutic antibodies against multiple targets. Twist Bioscience Corporation was incorporated in 2013 and is headquartered in South San Francisco, California.

TWST Income Statement

2022-09-30

Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2020
Statement of Comprehensive Income [Abstract]
Revenues	$ 203,565	$ 132,333	$ 90,100
Operating expenses:
Cost of revenues	119,330	80,620	61,406
Research and development	120,307	69,072	43,006
Selling, general and administrative	212,949	135,901	103,267
Change in fair value of contingent considerations and holdbacks	(14,245)	(534)	0
Litigation settlement	0	0	22,500
Total operating expenses	438,341	285,059	230,179
Loss from operations	(234,776)	(152,726)	(140,079)
Interest income	3,062	435	1,499
Interest expense	(80)	(367)	(787)
Gain on deconsolidation of subsidiary	4,607	0	0
Other income (expense), net	(1,087)	(1,370)	(182)
Loss before income taxes	(228,274)	(154,028)	(139,549)
Benefit from (provision for) income taxes	10,411	1,930	(382)
Net loss attributable to common stockholders	(217,863)	(152,098)	(139,931)
Other comprehensive loss:
Change in unrealized gain (loss) on investments	(1,594)	(14)	(34)
Foreign currency translation adjustment	(795)	473	(60)
Comprehensive loss	$ (220,252)	$ (151,639)	$ (140,025)
Net loss per share attributable to common stockholders—basic (in dollars per share)	$ (4.04)	$ (3.15)	$ (3.57)
Net loss per share attributable to common stockholders—diluted (in dollars per share)	$ (4.04)	$ (3.15)	$ (3.57)
Weighted average shares used in computing net loss per share attributable to common stockholders—basic (in shares)	53,885	48,251	39,190
Weighted average shares used in computing net loss per share attributable to common stockholders—diluted (in shares)	53,885	48,251	39,190

TWST Balance Sheet

2022-09-30

Consolidated Balance Sheets - USD ($)	Sep. 30, 2022	Sep. 30, 2021
Current assets:
Cash and cash equivalents	$ 378,687,000	$ 465,829,000
Short-term investments	126,281,000	12,034,000
Accounts receivable, net	40,294,000	28,549,000
Inventories	39,307,000	31,800,000
Prepaid expenses and other current assets	11,914,000	8,283,000
Total current assets	596,483,000	546,495,000
Property and equipment, net	139,441,000	44,122,000
Operating lease right-of-use assets	74,948,000	61,580,000
Goodwill	85,811,000	22,434,000
Intangible assets, net	59,738,000	18,262,000
Restricted cash, non-current	1,572,000	1,530,000
Other non-current assets	3,385,000	7,674,000
Total assets	961,378,000	702,097,000
Current liabilities:
Accounts payable	20,092,000	14,900,000
Accrued expenses	10,169,000	6,437,000
Accrued compensation	27,023,000	22,327,000
Current portion of operating lease liability	13,642,000	8,213,000
Current portion of long-term debt	0	1,552,000
Other current liabilities	19,737,000	9,623,000
Total current liabilities	90,663,000	63,052,000
Operating lease liability, net of current portion	81,270,000	53,156,000
Other non-current liabilities	60,000	5,068,000
Total liabilities	171,993,000	121,276,000
Commitments and contingencies
Stockholders’ equity
Common stock, $0.00001 par value — 100,000 and 100,000 shares authorized at September 30, 2022 and 2021, respectively; 56,523 and 49,499 shares issued and outstanding at September 30, 2022 and 2021, respectively	0	0
Additional paid-in capital	1,619,644,000	1,190,828,000
Accumulated other comprehensive (loss)/income	(1,843,000)	546,000
Accumulated deficit	(828,416,000)	(610,553,000)
Total stockholders’ equity	789,385,000	580,821,000
Total liabilities and stockholders’ equity	$ 961,378,000	$ 702,097,000